Connect with us

Technology

**XingImaging Unveils NX PET Camera to Advance Parkinson’s Disease Research**

Published

on

NEW HAVEN, Conn., May 6, 2025 /PRNewswire/ — XingImaging, a MITRO company, a pioneer in advanced research imaging, radiopharmaceutical services, and medical imaging technology, proudly announces the launch of the **NX PET Camera**, a breakthrough in positron emission tomography (PET) imaging designed to accelerate research into critical biomarkers for Parkinson’s disease.

The **NX PET Camera** offers cutting-edge imaging capabilities, providing researchers with unparalleled precision in detecting and tracking neurodegenerative biomarkers. With **high-resolution PET imaging**, **advanced AI-driven data analysis**, and **enhanced biomarker mapping**, the NX PET Camera is set to revolutionize the study of Parkinson’s disease progression and therapeutic response.

“Early and accurate biomarker detection is key to advancing our understanding and treatment of Parkinson’s disease,” said Gilles Tamagnan, CEO of XingImaging. “The NX PET Camera delivers the next-generation imaging technology needed to support groundbreaking research and improve patient outcomes.”

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) funded XingImaging researchers with an aim to use PET imaging  to visualize changes in the dopamine pathway of the brain to collect data about PD. Jamie Eberling, PhD, senior vice president of research resources at MJFF, said of the camera’s launch, “There’s been monumental progress in the last few years through strong investments in finding tracers that can show us alpha-synuclein and other targets in the living brain. This high-resolution PET imaging technology magnifies the impact of these tracers by improving what we can see in real-time. The field is energized by the latest milestones in imaging getting us closer to a day where we can clearly measure, quantify and visualize brain pathology in Parkinson’s disease.”

The NeuroExplorer PET camera from United Imaging is a next-generation ultra-high performance human brain PET imager scanner offering unparalleled resolution (1.4 mm FWHM) and sensitivity (46 kcps/MBq) in the study of brain function. This promises to be revolutionary for imaging of neurodegenerative diseases, like Parkinson’s & Alzheimer’s, and psychiatric diseases enabling high signal to noise imaging even for small brain structures. XingImaging’s NeuroExplorer PET camera enhances the company’s delivery of the highest quality science for its research and drug development partners.

Key Features of the NX PET Camera:

**Ultra-High-Resolution Imaging**: Enables precise visualization of neurodegenerative biomarkers.**AI-Powered Data Analysis**: Advanced machine learning algorithms enhance image interpretation and diagnostic accuracy.**Dynamic Biomarker Mapping**: Provides real-time insights into brain activity and disease progression.**Non-Invasive & Efficient**: Minimizes patient discomfort while delivering rapid, high-quality results.

About XingImaging

XingImaging is a pioneer in medical imaging technology, committed to advancing healthcare research through innovative solutions. By developing state-of-the-art imaging systems, the company supports researchers and clinicians in their mission to improve

XingImaging, a subsidiary of MITRO, is a leading provider of advanced research imaging and radiopharmaceutical services. With a firm focus on quality and innovation, the company offers comprehensive clinical trial imaging services, core lab services, and radiotracer manufacturing. By maintaining the highest industry standards, XingImaging partners with research pharmaceutical and biotech organizations to drive breakthroughs in medical diagnostics and treatment diagnostic accuracy and therapeutic outcomes for neurological diseases.

About MITRO

MITRO is a molecular imaging contract research organization (MI-CRO) company in China. MITRO provides outstanding contract research for new drug development using radiolabeling and molecular imaging techniques. MITRO merged with XingImaging in 2023 to create one company dedicated to providing a full spectrum of CRO & CDMO research service offerings.

New Haven Facility

Our New Haven facility offers a comprehensive range of services, including:

Clinical Trial Services: State-of-the-art Clinic providing consistent, compassionate, and high-quality services to research participants to support clinical trials.

Advanced Imaging Services: Advanced imaging technologies designed and implemented with an emphasis on precision and quality, including PET and SPECT.

Radiotracer Manufacturing: Tailored GMP production to meet the precise needs of clinical trials with stringent quality control.

Leading Imaging Analysis Services: Tailored analysis pipelines that focus on maximizing signal-to-noise, robustness and reproducibility.

XingImaging’s commitment to excellence is reflected in every aspect of the new facility’s operations, ensuring that participants, sponsors, and collaborators receive the highest quality of service.

The NX PET Camera is now available for research institutions, hospitals, and pharmaceutical partners aiming to accelerate biomarker discovery and drug development for Parkinson’s disease and other neurodegenerative disorders.

View original content to download multimedia:https://www.prnewswire.com/news-releases/xingimaging-unveils-nx-pet-camera-to-advance-parkinsons-disease-research-302447456.html

SOURCE XingImaging, LLC

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BlueNexus Technologies Unveils AquaX Hub at SIWW 2026 — AI Autonomous Operations Extended to Legacy Water Assets

Published

on

By

SINGAPORE, June 21, 2026 /PRNewswire/ — At Singapore International Water Week (SIWW) 2026, BlueNexus Technologies unveiled the global debut of AquaX Hub™ — a compact plug-and-play edge device that brings full AI-powered autonomous operation to standalone water equipment and legacy treatment plants. The launch drew sustained engagement from utilities, industrial operators and engineering firms.

The water sector confronts converging pressures: aging infrastructure, a critical shortage of skilled technicians, and relentless operational cost escalation. AquaX Hub™ answers these directly — extending the AI autonomous operation already proven plant-wide by AquaX Robot™ to a single asset, and delivering comparable monitoring and operational management without a control-system overhaul.

“The industry cannot hire its way out of this problem,” said Jack Zhang, CEO of BlueNexus Technologies. “AI autonomous operation is no longer a future concept — the barrier to entry is gone.”

The AquaX Ecosystem

BlueNexus has built the industry’s first fully integrated AI autonomous water operation platform, spanning three complementary pillars:

AquaX Robot™ is the flagship plant-wide AI agent, built on large language models with proprietary vision, acoustic and infrared multimodal sensing. It optimizes treatment processes 24/7 and predicts equipment failures. Live deployments show up to 90% reduction in on-site staffing, a 50% drop in equipment breakdowns, and approximately 35% lower O&M costs.

AquaX Hub™, making its global debut at SIWW 2026, is a lightweight edge terminal extending that capability to any water system. With an independent local processing module, it monitors and inspects equipment through multimodal sensing and runs a self-contained processing loop. The device integrates seamlessly with existing SCADA, cloud and enterprise platforms via standardized APIs.

i-WaterHub™, the company’s standardized modular treatment plant, operated autonomously by AquaX Robot, delivers 2,500 to 40,000 m³/day for municipal and industrial applications.

Market Momentum

SIWW 2026 convened nearly 500 exhibitors from over 65 countries. BlueNexus has identified priority markets for AquaX Hub™ in Southeast Asia, the Middle East and Africa. “The conversations this week have already translated into concrete business opportunities and we expect rapid deployment in the coming months.” Zhang confirmed.

About BlueNexus Technologies

BlueNexus Technologies is a Singapore-based water-technology company building intelligent, AI-operated systems for the world’s most water-intensive industries. We design and deliver modular water treatment infrastructure that is smarter to run, faster to deploy, and built to operate autonomously.

Web: www.bluenexus.tech

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/bluenexus-technologies-unveils-aquax-hub-at-siww-2026–ai-autonomous-operations-extended-to-legacy-water-assets-302805849.html

SOURCE BlueNexus Technologies

Continue Reading

Technology

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS

Published

on

By

With the presence of Emmanuel Macron and Narendra Modi, Prime Minister of India

PARIS, June 20, 2026 /CNW/ — From June 17 to 20, 2026 at Paris Porte de Versailles, VivaTech celebrated its 10th edition, surpassing the exceptional milestone of 200,000 visitors from 165 nationalities, with more than 15,000 startups present, 1,155 speakers and over 5 billion cumulative impressions on social media. Europe’s largest tech and innovation event has reached a new dimension, consolidating its status as an unmissable global gathering.

Exceptional speakers

VivaTech welcomed the greatest figures in global tech: Jeff Bezos (Amazon & Blue Origin), Dave Limp (Blue Origin), Bernard Arnault (LVMH), Henna Virkkunen (European Commission), Ekaterina Zaharieva (European Commission). Germany, Country of the Year 2026, was represented by a ministerial delegation, while India, AI Country Partner 2026, was led by Prime Minister Narendra Modi, as a continuation of the AI Summit in New Delhi.

Innovation and business at the heart of the event

More than 4,500 exhibitors, 61% of whom were international, showcased their latest innovations. Among the standout innovations: the smart contact lens by XPANCEO, the thought-controlled humanoid robot by Unitree x HABS, and the 3D-printed resorbable implants by Lattice Medical. New formats such as the Business Plaza and Investors Office Hours further accelerated business connections.

The VivaTech x Bloomberg Awards

For the first time, VivaTech presented the VivaTech x Bloomberg Awards, recognising the most influential figures in global tech, including Sir Tim Berners-Lee (Visionary Award), Joe Tsai (Leadership Award) and Yann LeCun (Momentum Award).

Innovation open to all

VivaTech also took over the Champs-Élysées on June 14th for an open-air technology showcase, before opening its doors to the general public on June 20th with astronaut Thomas Pesquet as guest star.

“This 10th edition was not a celebration of the 9 previous years, but the opening of a new decade full of promise.” — Maurice Lévy, Michèle Benbunan & François Bitouzet, VivaTech

See you from June 16 to 19, 2027 at Paris Expo Porte de Versailles for VivaTech 2027!

About VivaTech

VivaTech accelerates innovation by connecting startups, tech leaders, major companies, and investors responding to our world’s biggest challenges.  

Each year, over four exciting days in Paris, VivaTech creates Europe’s biggest startup and tech event, exploring the most disruptive topics in tech with world-premiere demos, launches, and conferences in a collaborative ecosystem. This is where business meets innovation. Join us for the eleventh edition of VivaTech 16-19 June 2027.

For more information go to our website at https://vivatech.com/media or follow us on social media @VivaTech.

Contact
press@vivatechnology.com 

Logo: https://mmx.prnewswire.com/media/MS1865564/VT_LOGO_EN.jpg
Photo : https://mmx.prnewswire.com/media/MS1869778/VivaTech_2026.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/vivatech-2026-celebrates-its-10th-anniversary-with-a-record-edition-surpassing-200-000-visitors-302805827.html

SOURCE VivaTech

Continue Reading

Technology

Pope Leo XIV embraces paediatric patients at CNAO in Pavia

Published

on

By

PAVIA, Italy, June 20, 2026 /PRNewswire/ — The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV’s pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific progress and the alleviation of human suffering.

CNAO President Gianluca Vago and General Manager Sandro Rossi received His Holiness, illustrating the center’s distinctive capabilities. CNAO stands out as a unique reality in Italy, remaining one of the very few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions. The technological core of the facility is its synchrotron, a subatomic particle accelerator that generates ultra-high-precision beams to treat complex, inoperable and radioresistant tumours. This cutting-edge technology allows for the targeted eradication of diseased cells while meticulously preserving surrounding healthy tissues, drastically improving patients’ survival and quality of life.

Furthermore, CNAO is expanding its capabilities as a premier multi-center utilizing new ion species, like Helium, later Oxygen and Neon. Soon, treatments will incorporate the Leo Cancer Care upright positioning and imaging system. The immediate future also includes beginning therapies with a Hitachi dedicated proton accelerator and gantry and a BNCT system for metastatic diseases, equipped with an electrostatic accelerator produced by TAE Life Science. With these new technologies, CNAO will become one of the most technologically advanced center in the world.

To date, over six thousand individuals, including approximately three hundred children and adolescents, have benefited from these life-saving treatments.

During his visit, the Pope engaged with CNAO’s Board of Directors, a collaborative body uniting national universities, clinical institutions, and research centers. He also extended his heartfelt greetings to the two hundred employees of the center. These doctors, physicists, engineers, and researchers tirelessly operate the advanced technologies in the service of oncology patients.

The emotional pinnacle of the day was the Holy Father’s private gathering with a delegation of young children who underwent treatment. The paediatric patients and their families shared a deeply touching moment of closeness, receiving the Pope’s comforting embrace.

“The visit of Pope Leo XIV honours us and represents a moment of extraordinary human value”, stated CNAO President Gianluca Vago. “In his encyclical Magnifica Humanitas, the Holy Father emphasizes the necessity of a science that constantly safeguards the centrality of the person and directs technology toward the common good. In a time marked by global tensions, CNAO testifies daily how the incredible power of the atom can be used not to destroy, but to heal. The particle beams we utilize against disease are, symbolically, Rays of Hope, sharing and supporting the IAEA project bearing this name. The embrace the Holy Father reserved for our children reminds us that scientific research finds its most authentic purpose when it encounters listening, compassion, and hope”.

Photo – https://mma.prnewswire.com/media/2997869/Papa_al_Cnao_crediti_Andrea_Perotti.jpg
Logo – https://mma.prnewswire.com/media/2997643/CNAO_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/pope-leo-xiv-embraces-paediatric-patients-at-cnao-in-pavia-302805799.html

Continue Reading

Trending